Jim Jasper

Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

|

The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in … Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share positive topline results from the Phase 3 PHOENYCS GO study evaluating the investigational therapy dapirolizumab pegol in people living with moderate-to-severe systemic lupus. Results of the Phase 3 PHOENYCS GO study were reported by study sponsors UCB and Biogen. The … Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

Statement in Response to Recent Lupus Science and Medicine Publication

|

A study recently published in Lupus Science and Medicine showed that krill oil concentrate helped to increase Omega-3 deficiency in people living with lupus. Secondary findings on a small subset of people with more severe lupus in the ORKIDS study suggest that krill oil concentrate may impact disease activity, but further study is warranted. Lupus … Statement in Response to Recent Lupus Science and Medicine Publication

On “Lupus Call to Action Day”, the Lupus Research Alliance and Lupus Therapeutics Amplify a Call for Equity and Inclusion

|

As part of Lupus Awareness Month, May 1 has been declared “Lupus Call to Action Day” by the National Minority Health Association (NMHA) and members of the lupus community. Kicking off at NYU Langone Health in New York City, the high-profile platform is designed to drive awareness and enact change to improve equity and inclusion … On “Lupus Call to Action Day”, the Lupus Research Alliance and Lupus Therapeutics Amplify a Call for Equity and Inclusion

Lupus Peer-to-Peer Early Education Program Expands

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced an innovative expansion of the highly successful Patient Advocates for Lupus Studies (PALS) program with the introduction of a first-in-lupus “Trial Buddy” component made possible by a partnership with Bristol Myers Squibb. The Trial Buddy addition provides extra support to people with … Lupus Peer-to-Peer Early Education Program Expands

Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation of the kidneys caused by lupus. AlloNK … Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

Summary Highlights of Important Research Presented at ACR Convergence 2023

|

At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is Showing Great … Summary Highlights of Important Research Presented at ACR Convergence 2023

Positive One-Year Results of PALS Program Published in Prestigious Rheumatology Journal

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share that the successful results of the Patient Advocates for Lupus Studies (PALS) pilot study were recently published in ACR Open Rheumatology , the official open-access journal of the American College of Rheumatology. The PALS (Patient Advocates for Lupus Studies) Program was … Positive One-Year Results of PALS Program Published in Prestigious Rheumatology Journal

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support Nkarta in early … Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network 

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ®) in individuals living with systemic lupus erythematosus (SLE). In this partnership, Lupus Therapeutics will assist with study participant recruitment, site activation and engagement efforts through the Lupus Clinical Investigators … Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network 

Lupus Therapeutics PALS Program Expansion

|

Call for Individuals to Serve as a Trained Peer Educator Lupus Therapeutics, the clinical affiliate of Lupus Research Alliance, is pleased to announce the expansion of the highly successful Patient Advocates for Lupus Studies (PALS) pilot program with an exciting request for people who have clinical trial experience as well as a lupus diagnosis to … Lupus Therapeutics PALS Program Expansion

Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia to Increase Diversity in Lupus Clinical Research

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced the launch of three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. The sites selected to participate in the pilot include Emory … Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia to Increase Diversity in Lupus Clinical Research